share_log

国信证券4月23日发布研报称，给予祥生医疗（688358.SH）买入评级。评级理由主要包括：1）2023年业绩增长较快，2024年一季度受2023年同期高基数影响；2）费用率下降，归母净利率提升；3）便携式设备放量驱动海外业务增长；4）布局人工智能前沿技术，产品处于临床试验阶段。（每日经济新闻）

Guoxin Securities released a research report on April 23 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance grew rapidly, and the first quarter of 2024 was affected by th

Zhitong Finance ·  Apr 24 13:12
Guoxin Securities released a research report on April 23 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance grew rapidly, and the first quarter of 2024 was affected by the high base for the same period in 2023; 2) the cost ratio declined and the net interest rate increased; 3) the volume of portable devices driven overseas business growth; 4) the layout of cutting-edge artificial intelligence technology, and the product is in the clinical trial stage. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment